# SWOG S1418 / NRG BR006

Source: https://onco.cc/trials/swog-s1418/  
OnCo record `swog-s1418` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SWOG S1418 is the trial that will say whether a year of pembrolizumab after surgery, on its own, helps women whose triple-negative breast cancer survived pre-operative chemotherapy. It finished recruiting 1,195 patients and is due to report from 2026.

## Summary

SWOG S1418/NRG BR006 (NCT02954874) randomised 1,195 patients with triple-negative breast cancer and residual invasive disease of at least 1 cm or positive lymph nodes (ypN1mi to ypN3) after neoadjuvant chemotherapy to one year of pembrolizumab or observation, with radiotherapy per standard of care; the primary endpoint is invasive disease-free survival, with fatigue and physical function as co-primary patient-reported endpoints. It opened in January 2017, before KEYNOTE-522 made neoadjuvant pembrolizumab standard, so it isolates the adjuvant contribution of pembrolizumab in a population that has not had it before surgery, a question KEYNOTE-522 could not answer. The registry lists primary completion in August 2026 and the trial as active, not recruiting; no results were indexed in September 2026. In England the matching NICE appraisal, pembrolizumab as adjuvant treatment after neoadjuvant chemotherapy (GID-TA11724), is awaiting development.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: S1418; NRG-BR006; SWOG S1418
- Registry id: NCT02954874
- Phase: 3
- Setting: Triple-negative breast cancer with residual invasive disease of 1 cm or more, or positive lymph nodes, after neoadjuvant chemotherapy without immunotherapy: one year of adjuvant pembrolizumab versus observation, United States, Canada and Puerto Rico
- Sponsor: National Cancer Institute (NCI), SWOG and NRG Oncology
- Enrolled: 1195

## Notes

- Key facts: adjuvant pembrolizumab for one year versus observation after residual disease of 1 cm or more or node-positive disease following neoadjuvant chemotherapy; primary endpoint invasive disease-free survival; 1,195 enrolled; primary completion August 2026 (registry); no results in September 2026.

## Sources

- ClinicalTrials.gov NCT02954874: https://clinicaltrials.gov/study/NCT02954874

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [SWOG Cancer Research Network](https://onco.cc/companies/swog/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- terms: [Event-free / disease-free survival (EFS, DFS, iDFS, RFS)](https://onco.cc/terms/efs/), [Residual cancer burden (RCB)](https://onco.cc/terms/rcb/), [Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point](https://onco.cc/terms/tnbc-residual-disease-decision/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- trials: [A-BRAVE](https://onco.cc/trials/a-brave/), [ALEXANDRA / IMpassion030](https://onco.cc/trials/impassion030/), [KEYNOTE-522](https://onco.cc/trials/keynote-522/)

---
JSON: https://onco.cc/api/v1/entities/swog-s1418.json